24/7 Market News Snapshot 23 October, 2024 – BioVie, Inc. Common Stock (NASDAQ:BIVI)

October 23, 2024

DENVER, Colo., 23 October, 2024 (247marketnews.com) – (NASDAQ:BIVI) are discussed in this article.
BioVie, Inc. (BIVI) has recently captured significant attention in the financial markets, experiencing a remarkable surge in pre-market trading where its shares climbed to $4.103, representing a notable 22.11% increase from the previous closing price of $3.360. This robust trading activity, with 5.23 million shares changing hands, underscores a growing investor confidence bolstered by positive market sentiment regarding BioVie’s innovative research and strategic undertakings.

In conjunction with this momentum, BioVie has announced an upcoming investor webinar scheduled for November 7, 2024, at 4:15 p.m. ET. This pivotal event, hosted by RedChip Companies, will feature insights from Cuong Do, President and CEO of BioVie. Attendees can expect critical updates on the company’s pipeline, which includes advanced mid-to-late-stage clinical programs targeting neurological disorders such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and long COVID (LC), alongside initiatives addressing advanced liver disease.

Central to BioVie’s advancements is bezisterim (formerly NE3107), the company’s lead candidate that demonstrates promising clinical results. Research indicates that bezisterim significantly alleviates inflammation and insulin resistance, while improving motor functionality in PD patients and mitigating cognitive decline in AD cases. Noteworthy clinical trials are on the horizon, with a Phase 2b trial for PD set for late 2024 or early 2025, and an exploratory Phase 2 trial in LC backed by a grant from the U.S. Department of Defense anticipated to commence in early 2025. Furthermore, BioVie plans to initiate a Phase 3 trial for AD with a reformulated daily dosage in late 2025.

In line with its growth strategy, BioVie is actively pursuing partnerships to secure geographical rights for bezisterim and is preparing to launch a Phase 3 trial for BIV201, which focuses on continuous infusion terlipressin, contingent upon identifying a suitable collaborative partner.

Related news for (BIVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.